DUBLIN--(BUSINESS WIRE)--Sep 13, 2018--The "Global Insomnia Treatment Drugs Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2018 To 2026" report has been added to ResearchAndMarkets.com's offering.

The global insomnia treatment drugs market was valued at US$ 2,689.6 million in 2017, and is expected to reach US$ 4,332.4 million by 2026, expanding at a CAGR of 5.5% from 2018 to 2026.

Pharmaceutical companies are relentlessly working to provide effective medication with least side effects. Orexin antagonist (Belsomra) are being prescribed by physicians throughout the globe owing to its ability to improve sleep with high degree of tolerability and limited adverse effects profile. The insomnia treatment drugs market pose severe threat from alternative treatment such as cognitive behavioral therapy for insomnia (CBTI) and recent FDA approval of devices such as Fisher Wallace Stimulator and EBB Insomnia Therapy.

Prescription sleep aids dominate the treatment type segment on account of key factors such as rising prevalence of insomnia, increasing stress, addiction, etc., which if untreated will eventually result in chronic illness. Demanding lifestyle and poor sleeping habits result in secondary insomnia which requires benzodiazepines in combination with zolpidem for its treatment.

Key Market Movements

Increasing number of geriatric population suffering with sleep disorders in the developed nations Affordable reimbursement scenario for drugs prescribed in insomnia treatment Growing health awareness leading to effective insomnia treatment, and developing healthcare infrastructure drive the market growth in developing nations

Key Topics Covered

Chapter 1. Preface

Chapter 2. Executive Summary

Chapter 3. Insomnia Treatment Drugs Market: Dynamics and Future Outlook

Chapter 4. Global Insomnia Treatment Drugs Market, by Treatment Type

Chapter 5. Global Insomnia Treatment Drugs Market, by Geography

Chapter 6. Company Profiles

F.Hoffman La-Roche AG Merck & Co. Inc. Mylan N.V. Pernix Therapeutics Pfizer Inc. Sanofi S.A. Sumitomo Dainippon Pharma Co. Ltd. Takeda Pharmaceutical Company Ltd. Teva Pharmaceutical Industries Ltd. Vanda Pharmaceuticals Inc.

For more information about this report visit https://www.researchandmarkets.com/research/84l79n/the_global?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180913005651/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Central Nervous System Drugs

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 09/13/2018 10:18 AM/DISC: 09/13/2018 10:18 AM

http://www.businesswire.com/news/home/20180913005651/en